Biomarker evaluation in phase I clinical trials of selective PI3K and PI3k/mTOR inhibitors

被引：0
|
作者：
Spoerke, Jill [1 ]
Desai, Rupal [1 ]
Patel, Rajesh [1 ]
Fredrickson, Jill [1 ]
Wang, Yulei [1 ]
Levy, Gallia [1 ]
Gendreau, Steve [1 ]
Lauchle, Jennifer [1 ]
Derynck, Mika [1 ]
Raja, Rajiv [1 ]
Koeppen, Hartmut [1 ]
Hampton, Garret [1 ]
Yan, Yibing [1 ]
Lackner, Mark R. [1 ]
机构：
[1] Genentech Inc, San Francisco, CA 94080 USA
来源：
CANCER RESEARCH | 2013年 / 73卷 / 08期
关键词：
D O I：
10.1158/1538-7445.AM2013-4567
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4567
引用
收藏
页数：1
相关论文
共 50 条
  • [21] The role of PI3K as a biomarker
    Amatulli, Michael
    Brennan, Laura A.
    Deevi, Dhanvanthri S.
    Prewett, Marie
    Tonra, James R.
    Paz, Keren
    CANCER RESEARCH, 2010, 70
  • [22] The Role of PI3kγ and PI3kΔ in Alloimmunity
    Uehara, M.
    Jamil, A.
    Solhjou, Z.
    McGrath, M.
    Banouni, N.
    Evans, C.
    Dinitto, J.
    Winkler, D.
    Abdi, R.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2016, 16 : 325 - 325
  • [23] The role of PI3kγ and PI3kδ in alloimmunity
    Uehara, Mayuko
    Jamil, Azzi
    Ohori, Shunsuke
    Solhjou, Zhabiz
    McGrath, Martina
    Banouni, Naima M.
    Evans, Catherine A.
    Dinitto, Jonathan P.
    Winkler, David G.
    Abdi, Reza
    TRANSPLANTATION, 2016, 100 (07) : S361 - S361
  • [24] A novel potent and selective inhibitor of PI3K/mTOR, GDC-0980, currently in phase I clinical trials
    Friedman, Lori S.
    Belvin, Marcia
    Berry, Leanne
    Berry, Megan
    Castanedo, Georgette
    Edgar, Kyle
    Folkes, Adrian
    Guan, Jane
    Heffron, Tim
    Lesnick, John
    Lewis, Cris
    Nonomiya, Jim
    Olivero, Alan
    Patel, Sonal
    Pang, Jodie
    Prior, Wei Wei
    Salphati, Laurent
    Sampath, Deepak
    Sutherlin, Dan
    Wallin, Jeff
    Zhu, Bingyan
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
  • [25] Discovery of Potent and Selective PI3Kγ Inhibitors
    Drew, Samuel L.
    Thomas-Tran, Rhiannon
    Beatty, Joel W.
    Fournier, Jeremy
    Lawson, Kenneth, V
    Miles, Dillon H.
    Mata, Guillaume
    Sharif, Ehesan U.
    Yan, Xuelei
    Mailyan, Artur K.
    Ginn, Elaine
    Chen, Jie
    Wong, Kent
    Soni, Divyank
    Dhanota, Puja
    Chen, Pei-Yu
    Shaqfeh, Stefan G.
    Meleza, Cesar
    Pham, Amber T.
    Chen, Ada
    Zhao, Xiaoning
    Banuelos, Jesus
    Jin, Lixia
    Schindler, Ulrike
    Walters, Matthew J.
    Young, Stephen W.
    Walker, Nigel P.
    Leleti, Manmohan Reddy
    Powers, Jay P.
    Jeffrey, Jenna L.
    JOURNAL OF MEDICINAL CHEMISTRY, 2020, 63 (19) : 11235 - 11257
  • [26] Design and synthesis of dual PI3K/mTor inhibitors
    Olivero, Alan
    Heffron, Timothy
    Berry, Leanne
    Berry, Megan
    Castanedo, Georgette
    Chang, Christine
    Dotson, Jennafer
    Friedman, Lori
    Goldsmith, Richard
    Lesnick, John
    Lewis, Cristina
    Mathieu, Simon
    Nonomiya, Jim
    Pang, Jodie
    Peterson, David
    Prior, Wei Wei
    Salphati, Laurent
    Sampath, Deepak
    Sutherlin, Daniel
    Tsui, Vickie
    Ultsch, Mark
    Wang, Shumei
    Wiesmann, Christian
    Wong, Susan
    Zhu, Bing-Yan
    Chuckowree, Irina
    Folkes, Adrian
    Shuttleworth, Steve
    CANCER RESEARCH, 2009, 69
  • [27] Effect of specific PI3K/mTOR inhibitors in squamous lung cancer cells carrying PI3K alterations
    Bonelli, M.
    Cavazzoni, A.
    La Monica, S.
    Galetti, M.
    Caffarra, C.
    Cretella, D.
    Saccani, F.
    Fumarola, C.
    Alfieri, R.
    Petronini, P. G.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : S166 - S167
  • [28] PI3K/Akt/mTOR inhibitors in breast cancer
    Joycelyn JX Lee
    Kiley Loh
    Yoon-Sim Yap
    Cancer Biology & Medicine, 2015, (04) : 342 - 354
  • [29] PI3K/Akt/mTOR inhibitors in breast cancer
    Lee, Joycelyn J. X.
    Loh, Kiley
    Yap, Yoon-Sim
    CANCER BIOLOGY & MEDICINE, 2015, 12 (04) : 342 - 354
  • [30] PI3K/AKT/mTOR Inhibitors In Ovarian Cancer
    Mazzoletti, M.
    Broggini, M.
    CURRENT MEDICINAL CHEMISTRY, 2010, 17 (36) : 4433 - 4447
12345